New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

KARDIGAN INC (KARD) news

Stories the last two months, newest first

  1. Results ·

    Kardigan reports a third-quarter net loss of $58.6 million

    Kardigan reported $591.4 million in cash and investments at September 30, 2026, which it said would fund planned data readouts and Phase 3 starts through 2027. Third-quarter research and development expenses rose to $64.4 million, while net loss was $58.6 million, or 64 cents per share, beating analysts’ average estimate of an 80-cent-per-share loss.

    Reported by 2: Business Wire · Associated Press

  2. Other ·

    Kardigan completes enrollment and sets a 48-week assessment in its ataciguat trial

    Kardigan completed enrollment in the Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis. The primary endpoint, change in aortic valve calcium, will be assessed at Week 48, while a Week 24 internal interim analysis will inform Phase 3 planning. Topline results are expected in the second half of 2027.

    Reported by 2: Business Wire · MarketBeat

More headlines